The story of my CART pt as painted by her continues. Her latest (bottom right) shows ongoing need for neutrophils 2 years post #CART#lymsm
Her prior work in thread below @MCWCancerCenter
Primary results of @BMTCTN 1801 in @NatureMedicine
1. Mirobiome diversity (MiDv) at engraftment not predictive of NRM @1yr
2. Lower MiDv = β¬οΈOS
3. MiDv lower w/PTcy
4. GvHD prophy likely exert effects on both the Mi and immune compartments
https://t.co/3eMv3rioQ3
Did we really need to prove BTKis trump alloHCT as first therapy for 17pdel/TP53mut #CLL but we did it anyway :) https://t.co/2O5WUKbg5o @awandoc@CIBMTR
allo vs. CLL patients from RESONATE-17 and RESONATE Phase 3
Michigan Republicans, funded by Musk and other billionaires, have no answers to the struggles facing working families.
Instead they are resorting to Islamophobia and are running the most racist campaign in recent history.
Together, let's defeat bigotry and elect Abdul El-Sayed.
JUST PUBLISHED TODAY:
GVHD prophylaxis shapes T cell biology and immune reconstitution after HCT. Explore the latest @BMTCTN research here:
https://t.co/6AkmzZnYif
#HCT#GVHD#Research#CIBMTR#BMTCTN
New BMT CTN research sheds light on how GVHD prevention strategies influence immune recovery after hematopoietic cell transplant. Learn more: https://t.co/1VSVq4L8o3
#BMTCTN#GVHD#HCT#ClinicalResearch#Transplantation
The aging US population is presenting oncologists with a growing problem: how to treat this vulnerable population without compromising outcomes.
Read more from our latest feature, with insight from @MediHumdani, @MikkaelSekeres, and Ronald Levy.
β‘οΈ https://t.co/dBDQT2B9Wr